University of Bonn - Institute of Science and Ethics, Bonn, Germany.
Bioethics. 2021 Feb;35(2):118-124. doi: 10.1111/bioe.12837. Epub 2020 Dec 9.
Many countries have adopted new triage recommendations for use in the event that intensive care beds become scarce during the COVID-19 pandemic. In addition to establishing the exact criteria regarding whether treatment for a newly arriving patient shows a sufficient likelihood of success, it is also necessary to ask whether patients already undergoing treatment whose prospects are low should be moved into palliative care if new patients with better prospects arrive. This question has led to divergent ethical guidelines. This paper explores the distinction between withholding and withdrawing medical treatment during times of scarcity. As a first central point, the paper argues that a revival of the ethical distinction between doing and allowing would have a revisionary impact on cases of voluntary treatment withdrawal. A second systematic focus lies in the concern that withdrawal due to scarcity might be considered a physical transgression and therefore more problematic than not treating someone in the first place. In light of the persistent disagreement, especially concerning the second issue, the paper concludes with two pragmatic proposals for how to handle the ethical uncertainty: (1) triage protocols should explicitly require that intensive care attempts are designed as time-limited trials based on specified treatment goals, and this intent should be documented very clearly at the beginning of each treatment; and (2) lower survival prospects can be accepted for treatments that have already begun, compared with the respective triage rules for the initial access of patients to intensive care.
许多国家都采用了新的分诊建议,以应对在 COVID-19 大流行期间,重症监护床位可能变得稀缺的情况。除了确定关于新到患者的治疗是否有足够成功可能性的确切标准外,还需要询问如果有前景更好的新患者到达,是否应该将正在接受治疗但前景不佳的患者转移到姑息治疗中。这个问题导致了不同的伦理准则。本文探讨了在资源稀缺时期,在保留和停止治疗之间的区别。作为第一个核心观点,本文认为,恢复在积极治疗和消极放任之间的伦理区分,将对自愿停止治疗的情况产生修正性影响。第二个系统重点在于关注由于资源稀缺而停止治疗可能被视为一种身体侵犯,因此比最初不治疗患者更成问题。鉴于持续存在的分歧,尤其是在第二个问题上,本文最后提出了两种处理伦理不确定性的实用建议:(1)分诊方案应明确要求,重症监护尝试应设计为基于特定治疗目标的限时试验,并且在每次治疗开始时,都应非常清楚地记录这一意图;(2)与初始进入重症监护的患者的相应分诊规则相比,可以接受已经开始的治疗的较低生存率。